Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Erytech To Conduct Pancreatic Cancer Trial | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Erytech To Conduct Pancreatic Cancer Trial

Plans Ph. II study for 2Q14

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Erytech Pharma has launched a Phase II study of Eryasp in pancreatic cancer. Erytech completed a Phase I study in late-stage pancreas cancer, confirming  tolerability, and will continue the development in solid tumors by performing a Phase II study in second line pancreas cancer. In a study of about 100 patients, Eryasp in addition to the best standard of care will be compared to the best standard of care alone in a 2:1 randomization.

Thanks to an exclusive license from the National Institutes of Health (NIH) in the U.S., Erytech has a proprietary companion test allowing to identify the potential responders to treatment with asparaginase, with the plan of offering personalized treatment.

Patient enrollment is expected to start in 2Q14. Eryasp already holds orphan drug designation for the treatment of pancreas cancer in Europe and the U.S. Erysap is currently completing a Phase III trial in Acute Lymphoblastic Leukemia (ALL) and is in a Phase IIb trial in Acute Myeloid Leukemia (AML). The product has received FDA clearance to start clinical development in ALL in the U.S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics